অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - vilanterol trifenatate, quantity: 40 microgram (equivalent: vilanterol, qty 25 microgram); fluticasone furoate, quantity: 100 microgram - inhalation, powder for - excipient ingredients: magnesium stearate; lactose monohydrate - copd,breo ellipta is indicated for symptomatic treatment of patients with copd with a fev1 <70% predicted normal (post-bronchodilator) in patients with an exacerbation history despite regular bronchodilator therapy.,breo ellipta is not indicated for the initiation of bronchodilator therapy in copd.,asthma,breo ellipta is indicated in the regular treatment of moderate to severe asthma in patients who require a medium to high dose inhaled corticosteroid combined with a long-acting beta-2-agonist.,vilanterol, an active ingredient in breo ellipta, is a long-acting beta-2-agonist (laba). a class effect of all labas can be an increased risk of asthma death (see precautions).

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone furoate, quantity: 200 microgram; vilanterol trifenatate, quantity: 40 microgram (equivalent: vilanterol, qty 25 microgram) - inhalation, powder for - excipient ingredients: magnesium stearate; lactose monohydrate - asthma,breo ellipta is indicated in the regular treatment of moderate to severe asthma in patients who require a medium to high dose inhaled corticosteroid combined with a long-acting beta-2-agonist.,vilanterol, an active ingredient in breo ellipta, is a long-acting beta-2-agonist (laba). a class effect of all labas can be an increased risk of asthma death (see precautions).

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salbutamol sulfate, quantity: 6 mg (equivalent: salbutamol, qty 5 mg) - inhalation, conventional - excipient ingredients: water for injections; sodium chloride; sulfuric acid - for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise induced asthma or in other situations known to induce bronchospasm.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salbutamol sulfate, quantity: 3 mg (equivalent: salbutamol, qty 2.5 mg) - inhalation, conventional - excipient ingredients: water for injections; sulfuric acid; sodium chloride - for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise induced asthma or in other situations known to induce bronchospasm.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - tiotropium bromide monohydrate, quantity: 3.1235 microgram/actuation (equivalent: tiotropium, qty 2.5 microgram/actuation) - inhalation, conventional - excipient ingredients: purified water; hydrochloric acid; disodium edetate; benzalkonium chloride - copd: spiriva respimat is indicated for the long term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (copd). spiriva respimat is indicated for the prevention of copd exacerbations.,asthma: spiriva respimat is indicated as add-on maintenance bronchodilator treatment in patients aged 6 years and older with moderate to severe asthma.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 250 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: *patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids. *patients who are symptomatic on current inhaled corticosteroid therapy. for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. seretide is not indicated for the initiation of bronchodilator therapy in copd.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 125 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: *patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids. *patients who are symptomatic on current inhaled corticosteroid therapy. for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. seretide is not indicated for the initiation of bronchodilator therapy in copd.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 50 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: *patients on effective maintenance doses of long-acting beta-2-agonists and inhaled corticosteroids. *patients who are symptomatic on current inhaled corticosteroid therapy.*initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on "as needed" reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring medication every day (see clinical trials). for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. seretide is not indicated for the initiation of bronchodilator therapy in copd.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salbutamol sulfate, quantity: 6 mg (equivalent: salbutamol, qty 5 mg) - inhalation, conventional - excipient ingredients: sulfuric acid; water for injections; sodium chloride - for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise induced asthma or in other situations known to induce bronchospasm.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salbutamol sulfate, quantity: 3 mg (equivalent: salbutamol, qty 2.5 mg) - inhalation, conventional - excipient ingredients: water for injections; sulfuric acid; sodium chloride - for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise induced asthma or in other situations known to induce bronchospasm.